MiMedx Group, Inc (NASDAQ:MDXG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $8.50.

A number of research analysts have recently weighed in on the company. Wall Street Zen lowered MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Craig Hallum reduced their target price on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Citizens Jmp reduced their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Finally, Weiss Ratings cut shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th.

MiMedx Group Stock Up 3.1%

Shares of MDXG stock opened at $3.93 on Friday. The stock’s 50-day simple moving average is $3.59 and its 200-day simple moving average is $4.71. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The firm has a market capitalization of $585.37 million, a PE ratio of 19.65 and a beta of 1.48. MiMedx Group has a fifty-two week low of $3.03 and a fifty-two week high of $7.99.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%. Equities analysts expect that MiMedx Group will post -0.01 earnings per share for the current year.

Institutional Trading of MiMedx Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC grew its position in MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after buying an additional 1,725,458 shares during the period. Allspring Global Investments Holdings LLC grew its position in MiMedx Group by 433.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock valued at $1,958,000 after buying an additional 234,958 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in MiMedx Group during the fourth quarter valued at $7,134,000. Vanguard Group Inc. grew its position in MiMedx Group by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after buying an additional 382,623 shares during the period. Finally, World Investment Advisors acquired a new stake in MiMedx Group during the fourth quarter valued at $173,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.